<DOC>
	<DOCNO>NCT02543073</DOCNO>
	<brief_summary>Interstitial lung disease ( ILDï¼‰ late pulmonary complication allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) lead high morbidity mortality . At present , treatment ILD allo-HSCT remain discussion . In study , efficacy mesenchymal stem cell ( MSCs ) combine azithromycin well glucocorticoid treatment ILD evaluate recipient allo-HSCT .</brief_summary>
	<brief_title>MSC Treatment Interstitial Lung Disease After Allo-HSCT</brief_title>
	<detailed_description>ILD group diseases involve pulmonary interstitial , alveolar ( ) bronchiole . In patient receive allo-HSCT , ILD mainly present bronchiolitis obliterans syndrome ( BOS ) . ILD HSCT characterize non-responsiveness treatment , lead high morbidity mortality . MSC consider effective treatment refractory acute graft-versus-host disease ( aGVHD ) , response treat chronic GVHD ( cGVHD ) , especially refractory BOS , rarely report .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Receiving alloHSCT Diagnosed ILD alloHSCT Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>